[Retracted] Chemotherapy with a TP Regimen in Combination with Stereotactic Radiotherapy Could Significantly Optimize the Clinical Efficacy of NSCLC Treatment

Table 4

Detection results of serum CYFRA21-1 and MALAT1 levels.

Group		CYFRA21-1 (ng/mL)	MALAT1
Observation group	Pretreatment	4.58 ± 0.77	0.48 ± 0.11
	After treatment	2.18 ± 0.59	1.02 ± 0.22
Control group	Pretreatment	4.51 ± 0.65	0.47 ± 0.09
	After treatment	3.01 ± 0.54	0.82 ± 0.18